Richard J. Nowak, MD, MS

Inebilizumab's twice-yearly CD19 dosing directly targets antibody-producing cells; trial enrollment used disease activity, not treatment failure.

Even with MINT's mandatory steroid taper, inebilizumab still cut exacerbation and rescue therapy rates versus placebo, said Richard Nowak, MD, MS

Follow-up length varied by subgroup in the MINT trial, but inebilizumab cut exacerbations and rescue therapy use consistently.

Hospital resources, not clinical preference, often decide which MG rescue therapy a patient receives, Richard Nowak, MD, MS, said.

In this interview, Richard J. Nowak, MD, MS, principal investigator of the MINT trial of inebilizumab for generalized myasthenia gravis (gMG), discusses the trial’s key findings, including significant improvements in patient- and physician-assessed outcomes, as well as longer-term implications and future areas of investigation.

Richard J. Nowak, MD, MS, Yale School of Medicine, explains what some early myasthenia gravis symptoms are and their impact on research efforts.

The randomized control period of the MINT trial has completed, and these newest data describe outcomes among patients who have acetylcholine receptor antibody–positive generalized myasthenia gravis (AChR+ gMG), explained MINT principal investigator Richard Nowak, MD, MS, Yale School of Medicine.